Prospective Registry Study on the Implementation of Simultaneous Postoperative Radiochemotherapy for Salivary Gland Carcinomas of the Head and Neck Region

Inclusion Criteria:

• Salivary gland carcinomas of the major and minor salivary glands of the head andneck region

• High-grade histology

• Successful oncological resection with curative intent

• pT3-4 or pN1-3 or Pn1(perineural sheath infiltration) or pT1-2 with scarce orpositive resection margin

• cM0

• Indication for postoperative combined radiochemotherapy (guideline-compliantradiochemotherapy; percutaneous radiotherapy up to a total dose of 64-72 Gy (depending on resection status), common chemotherapy regimens: Paclitaxel 135mg/m²KOF d1 and cisplatin 33mg/m² KOF d1-3, q d22 or paclitaxel 135mg/m² KOF d1,carboplatin AUC 1.5 KOF d1-3 or paclitaxel 50mg/m² KOF, carboplatin AUC2 d1,8,15, qd22 or paclitaxel 50mg/m²KOF and cisplatin 30mg/m² KOF d1,8,15, q d22, 4 cycleseach).

• Patient age ≥18 years

• WHO performance score ≤ 1

• Signed patient information/consent form

Exclusion Criteria:

• Distant metastases

• Other cancer in the last 5 years prior to study inclusion (with the exception of:adequately treated skin cancer (except melanoma) or lentigo maligno or adequatelytreated carcinoma in situ, in each case without evidence of active disease).

• Previous chemotherapy or radiotherapy for salivary gland carcinoma

• Previous radiotherapy in the head and neck area

• Pre-existing uncontrolled disease that constitutes a contraindication tosimultaneous combination chemotherapy (e.g. signs of acute heart failure, myocardialinfarction within the last 6 months before the start of therapy, congestive heartfailure, heart disease with New York Heart Association (NYHA) III or IVclassification, active and therapy-resistant infection, pre-existing or concomitantimmunodeficiency syndrome)

• Pregnancy and breastfeeding

• Fertile patients who cannot ensure effective contraception during and up to sixmonths after combination therapy